PNC Financial Services Group’s Keros Therapeutics KROS Stock Holding History
Bought
Maintained
Sold
Other funds holding KROS
PNC Financial Services Group's KROS Position: Q3 2026 in Review
PNC Financial Services Group increased its Keros Therapeutics (KROS) stake by 347% in Q3 2026, buying an estimated $38K and bringing the position to 4,470 shares worth $51K. The position accounts for ﹤0.01% of the portfolio, ranked #3373.
PNC Financial Services Group first reported a position in KROS in Q4 2023 and has held it in 11 quarters since. 135 funds tracked by Wall St. Rank hold KROS as of Q3 2026.
- PNC Financial Services Group held 4,470 shares of Keros Therapeutics worth $51K as of Q3 2026.
- PNC Financial Services Group bought 3,471 Keros Therapeutics shares in Q3 2026, an estimated $38K.
- Keros Therapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q3 2026, its #3373 holding.
- PNC Financial Services Group first reported a position in Keros Therapeutics in Q4 2023 and has held it in 11 quarters since.
- 135 funds tracked by Wall St. Rank held Keros Therapeutics as of Q3 2026.
Based on PNC Financial Services Group's 13F filing for Q3 2026, filed 6 Nov 2026.